Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
